提示: 手机请竖屏浏览!

肿瘤中的选择性剪接——免疫原性的一个产生途径?
Alternative Splicing in Tumors — A Path to Immunogenicity?


Jill E. Slansky ... 肿瘤 • 2019.02.28

人类基因组约有2万个基因,但表达的细胞功能和分化所需蛋白质远超过这个数字。选择性剪接是产生额外信使RNA(mRNA),以翻译成不同蛋白质的过程之一。选择性剪接的转录物可导致翻译出略有差异的蛋白质或功能完全不同的蛋白质。一种被称为剪接体的蛋白质复合体负责典型剪接(canonical splicing,从RNA前体中去除非编码内含子)和选择性剪接。选择性剪接的一个典型例子是BCL2L11BCL2L11是编码BIM蛋白质的促凋亡人类基因,有6个外显子和至少18种不同的同种型(选择性剪接的mRNA翻译出的蛋白质变体)1(图1)。主要同种型BIMS、BIML和BIMEL具有不同的内部结构域,但编码相同的5'和3'外显子,它们分别产生相同的N-末端和C-末端结构域。不同的结构域为每种同种型分配不同的功能:BIMS具有最强的促凋亡作用,因为它能够结合BAX蛋白。与之相比,BIML和BIMEL可与抗凋亡蛋白BCL2相互作用。





作者信息

Jill E. Slansky, Ph.D., and Paul T. Spellman, Ph.D.
From the Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora (J.E.S.); and the Department of Molecular and Medical Genetics, Oregon Health and Science University, and the Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Portland (P.T.S.).

 

参考文献

1. Sionov RV, Vlahopoulos SA, Granot Z. Regulation of Bim in health and disease. Oncotarget 2015;6:23058-23134.

2. Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 2016;35:2413-2427.

3. Kahles A, Lehmann KV, Toussaint NC, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell 2018;34(2):211-224.e6.

4. Kahles A, Ong CS, Zhong Y, Rätsch G. SplAdder: identification, quantification and testing of alternative splicing events from RNA-Seq data. Bioinformatics 2016;32:1840-1847.

5. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.

服务条款 | 隐私政策 | 联系我们